Mitoxantrone hydrochloride liposome (CSPC ZhongQi)

Tier C — Watch / trade

Originator

2022

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：TOP2, Pim-1, NS3/NS4A

Brand：Duoenda

Indications (approved)：Peripheral T-cell lymphoma

Regional status

China

Approved

2022-01-07

Japan

Factories producing this API1

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

1 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Mitoxantrone hydrochloride liposome (CSPC ZhongQi)?

Approved indications include: Peripheral T-cell lymphoma.

When does the Mitoxantrone hydrochloride liposome (CSPC ZhongQi) patent expire?

No public expiry year is available for Mitoxantrone hydrochloride liposome (CSPC ZhongQi) yet; this page updates once verified.

How do I get a quote for Mitoxantrone hydrochloride liposome (CSPC ZhongQi) intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27